Status:
COMPLETED
Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Papillomavirus Infections
Eligibility:
FEMALE
9-15 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the safety and tolerability of the Quadrivalent Human Papilloma Virus (HPV) vaccine in healthy females 9 to 15 years of age in India. Quadrivalent HPV Vaccine ...
Eligibility Criteria
Inclusion
- Healthy Females Age 9 To 15 Years
- Females Not Sexually Active And Not Plan On Becoming Sexually Active During The Study
- No Fevers 24 Hours Prior To The First Injection
Exclusion
- Participant Had Received A Prior Vaccination With A HPV Vaccine
- Participant Has Allergies To Vaccine Component Including Aluminum And Yeast
- Participant Has (Human Immunodeficiency Virus) HIV Infection
- Participant Is Immunocompromised
- Participant Received Or Plans To Receive Blood-Derived Product Within 6 Months Prior To The First Injection
- Participant Received Or Plans To Receive Immune Globulin Preparation Within 6 Months To The First Injection
Key Trial Info
Start Date :
May 3 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 4 2008
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT00380367
Start Date
May 3 2007
End Date
February 4 2008
Last Update
May 31 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.